Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PTC Therapeutics, Inc. (PTCT : NSDQ)
 
 • Company Description   
PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

Number of Employees: 991

 
 • Price / Volume Information   
Yesterday's Closing Price: $68.81 Daily Weekly Monthly
20 Day Moving Average: 1,579,399 shares
Shares Outstanding: 82.95 (millions)
Market Capitalization: $5,707.72 (millions)
Beta: 0.53
52 Week High: $87.50
52 Week Low: $43.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.32% -4.58%
12 Week 1.04% -6.59%
Year To Date -9.41% -15.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 WARREN CORPORATE CENTER DRIVE
-
WARREN,NJ 07059
USA		 ph: 908-222-7000
fax: 908-222-7231		 ecavaleri@ptcbio.com http://www.ptcbio.com
 
 • General Corporate Information   
Officers
Matthew B. Klein - Chief Executive Officer and Director
Pierre Gravier - Chief Financial Officer
Christine Utter - Chief Accounting Officer
Michael Schmertzler - Director
Allan Jacobson - Director

Peer Information
PTC Therapeutics, Inc. (CORR.)
PTC Therapeutics, Inc. (RSPI)
PTC Therapeutics, Inc. (CGXP)
PTC Therapeutics, Inc. (BGEN)
PTC Therapeutics, Inc. (GTBP)
PTC Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 69366J200
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/06/26
Share - Related Items
Shares Outstanding: 82.95
Most Recent Split Date: (:1)
Beta: 0.53
Market Capitalization: $5,707.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.19 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 27.74% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 355.92
Trailing 12 Months: -
PEG Ratio: 12.83
Price Ratios
Price/Book: -
Price/Cash Flow: 7.84
Price / Sales: 6.90
EPS Growth
vs. Year Ago Period: -100.30%
vs. Previous Quarter: 98.20%
Sales Growth
vs. Year Ago Period: -76.83%
vs. Previous Quarter: 65.51%
ROE
03/31/26 - -
12/31/25 - -362.45
09/30/25 - -194.11
ROA
03/31/26 - -6.76
12/31/25 - 25.21
09/30/25 - 33.15
Current Ratio
03/31/26 - 2.44
12/31/25 - 2.35
09/30/25 - 2.32
Quick Ratio
03/31/26 - 2.36
12/31/25 - 2.27
09/30/25 - 2.26
Operating Margin
03/31/26 - -22.58
12/31/25 - 39.44
09/30/25 - 44.90
Net Margin
03/31/26 - -22.58
12/31/25 - 39.44
09/30/25 - 42.25
Pre-Tax Margin
03/31/26 - -28.49
12/31/25 - 40.25
09/30/25 - 41.65
Book Value
03/31/26 - -2.18
12/31/25 - -2.56
09/30/25 - -1.96
Inventory Turnover
03/31/26 - 1.03
12/31/25 - 1.00
09/30/25 - 1.71
Debt-to-Equity
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Capital
03/31/26 - -
12/31/25 - -
09/30/25 - -
 

Powered by Zacks Investment Research ©